权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Controlled Photochemical Release of Nitric Oxide for Biomedical Applications

用于生物医学应用的一氧化氮的受控光化学释放

基本信息

批准号：
10590662
负责人：
STEVEN P. SCHWENDEMAN
金额：
$ 46.36万
依托单位：
UNIVERSITY OF MICHIGAN AT ANN ARBOR
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-06-15 至 2025-02-28
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10590662
关键词：
Acute Respiratory Distress Syndrome Adhesives Affect Air Animal Testing Animals Antiviral Agents Apical Bacteria Biological Assay Blood Blood capillaries Cell Culture Techniques Cell surface Cells Chronic Chronic Obstructive Pulmonary Disease Clinical Cystic Fibrosis Cystic Fibrosis Transmembrane Conductance Regulator Devices Disease Dissociation Dose Electron Microscopy Electronics Epithelial Cells Exposure to Feedback Film Free Radicals Frequencies Funding Gases Generations Grant Histology Home Hospitals Human IL8 gene Individual Infection Inflammatory Intensive Care Ischemic Brain Injury Knockout Mice Lactate Dehydrogenase Light Lighting Link Lung Lung Transplantation Lung infections Malaria Medical Medicine Membrane Methemoglobin Methods Microbial Biofilms Modeling Monitor Morphology Mus Mutation Neonatology Nitric Oxide Nitric Oxide Donors Nitrogen Dioxide Orphan Drugs Outcome Output Particle Size Patients Performance Phase Pneumonia Polymers Population Porosity Prognosis Property Pseudomonas aeruginosa Pseudomonas aeruginosa infection Pulmonary Hypertension Pulmonary Tuberculosis Reaction Regimen Research Residual state Respiratory Tract Infections Risk S phase S-Nitrosothiols Signal Transduction Sinus Sinusitis Solid Sputum Stream Stroke Surface System Technology Testing Therapeutic Uses Tobramycin Toxic effect Vasodilator Agents X ray diffraction analysis airway epithelium antimicrobial antimicrobial drug cell preparation chronic rhinosinusitis controlled release cost crystallinity cystic fibrosis airway epithelia cystic fibrosis patients cytotoxic high risk in vitro testing in-home care infection risk inhaled nitric oxide light intensity light microscopy lung failure natural antimicrobial novel strategies particle portability pressure prevent prototype scale up sensor solid state

项目摘要

ABSTRACT: Therapeutic use of gas phase nitric oxide (NO) has several important applications in medicine. In addition to its well-known vasodilator action, NO is a potent and endogenous antimicrobial agent normally present at moderate levels (200-1000 ppbv) in the airways/sinuses of healthy individuals, which helps preventing chronic upper airway and lung infections. Since its first medical application >20 years ago, inhaled nitric oxide (iNO) has become a mainstay of intensive care for lung failure patients and it is essential in neonatology, lung transplantation, and pulmonary hypertension. It is also used in pneumonia, acute respiratory distress syndrome (ARDS), and potentially to treat of pulmonary tuberculosis and malaria. With the widespread hospital use of iNO there is a great potential for use of iNO also in the home for treating chronic pulmonary infections related to chronic obstructive pulmonary disease (COPD, ca. 11.5 million cases in US) and chronic rhino sinusitis (CRS, ca. 31 million cases in US). Further, while cases of cystic fibrosis (CF) is less common (ca. 30,000 cases), CF patients possess a genetic defect that greatly reduces NO levels liberated by airway epithelial cells, resulting in very high risk of infection. However, iNO therapy is presently exceedingly expensive (>$3,000 per day) owing to costly NO cylinders and the associated instability of NO in such gas tanks. Therefore, current NO delivery technology is both too expensive and non-portable for potential routine use for in-home care. Using funding from an exploratory R21 grant, our research team has developed a completely new and very attractive method for light-activated NO generation directly from solid phase S-nitrosothiols (RSNO) type NO donors. We have demonstrated that light-activated feedback-controlled release of NO can be achieved precisely from RSNO loaded polymer films combined with variable LED lighting. An amperometric NO selective sensor can provide signals for a feedback circuit to control the LED light intensity to achieve a target level of NO in the output air (or O2) stream. We have identified the main parameters affecting the efficiency of NO release from such films and for minimizing the emitted levels of toxic NO2 gas. In this R01 grant our team will further study the possibilities of scaling up the light-activated NO generation system. We will test the purity of the generated NO gas and the composition of the residual solid decomposition products in order to determine light triggered reaction mechanism of the NO release from the solid state RSNO species. We will study the antimicrobial and cytotoxic properties of the generated NO gas on bacteria infected human epithelial cells and in CFTR knockout mice. This new photochemical gas phase NO generation approach will be very attractive and much lower in cost than using current iNO delivery systems employing high pressure gas tanks. Indeed, photochemically generated NO could eventually be safely extended to in-home use for certain clinical situations (e.g., CF, COPD, CRS and ARDS) to prevent and treat chronic lung infections.

摘要：气相一氧化氮（NO）在医学上有几个重要的应用。在